<!DOCTYPE html><html lang="en"> <head><meta charset="UTF-8"><meta name="viewport" content="width=device-width"><meta name="robots" content="index,follow"><meta name="theme-color" content="#0b6457"><meta name="description" content="Curated papers, preprints, and scientific outputs from UIBCDF."><link rel="canonical" href="https://www.uibcdf.org/publications/"><link rel="icon" type="image/svg+xml" href="/favicon.svg"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16x16.png"><link rel="icon" type="image/png" sizes="192x192" href="/favicon-192x192.png"><link rel="apple-touch-icon" sizes="192x192" href="/favicon-192x192.png"><title>Publications | UIBCDF</title><meta property="og:type" content="website"><meta property="og:site_name" content="UIBCDF"><meta property="og:title" content="Publications | UIBCDF"><meta property="og:description" content="Curated papers, preprints, and scientific outputs from UIBCDF."><meta property="og:url" content="https://www.uibcdf.org/publications/"><meta property="og:image" content="https://www.uibcdf.org/og-default.svg"><meta name="twitter:card" content="summary_large_image"><meta name="twitter:title" content="Publications | UIBCDF"><meta name="twitter:description" content="Curated papers, preprints, and scientific outputs from UIBCDF."><meta name="twitter:image" content="https://www.uibcdf.org/og-default.svg"><link rel="stylesheet" href="/_astro/contact.Cwb6pq8P.css"></head> <body class="internal-page"> <header class="site-header"> <a class="brand" href="/" aria-label="UIBCDF home"> <img src="/logo-uibcdf.svg" alt="UIBCDF"> </a> <nav aria-label="Main navigation"> <ul> <li> <a href="/"> Home </a> </li><li> <a href="/research"> Research </a> </li><li> <a href="/team"> Team </a> </li><li> <a href="/publications" aria-current="page"> Publications </a> </li><li> <a href="/software"> Code </a> </li><li> <a href="/updates"> Updates </a> </li><li> <a href="/contact"> Contact </a> </li> </ul> </nav> </header> <div class="page-shell internal-page-shell"> <main> <section class="hero"> <h1>Publications</h1> <span class="hero-separator" aria-hidden="true"></span>  <p>Curated papers, preprints, and scientific outputs from UIBCDF.</p> <a class="cta" href="https://scholar.google.com/citations?user=TgOsFSQAAAAJ">UIBCDF Google Scholar</a> </section> <section class="content">  <section class="publications-page" aria-label="Publications directory"> <section class="publications-year" aria-label="Publications 2024" id="year-2024"> <h2> <a href="#year-2024">2024</a> </h2> <div class="publications-grid"> <article id="paper-2024-01" class="publication-card" style="--publication-body-img-width: 68%"> <div class="publication-media"> <img src="/_astro/thumbnail.5ODE-tNr.png" alt="First page thumbnail of publication" loading="lazy"> </div> <div class="publication-body"> <h3> <a href="#paper-2024-01">Exploring the Chemical Features and Biomedical Relevance of Cell-Penetrating Peptides</a> </h3> <p class="publication-authors">Liliana M. Moreno-Vargas<sup>*</sup> and Diego Prada-Gracia<sup>*</sup></p> <p class="publication-links"> <a href="https://doi.org/10.3390/ijms26010059" target="_blank" rel="noreferrer">
Print
</a>    </p> <details class="publication-details"> <summary> <span class="summary-closed">Show abstract</span> <span class="summary-open">Hide abstract</span> </summary> <div class="publication-body-expanded"> <p>Cell-penetrating peptides (CPPs) are a diverse group of peptides, typically composed of 4 to 40 amino acids, known for
their unique ability to transport a wide range of substances—such as small molecules, plasmid DNA, small interfering
RNA, proteins, viruses, and nanoparticles—across cellular membranes while preserving the integrity of the cargo. CPPs
exhibit passive and non-selective behavior, often requiring functionalization or chemical modification to enhance their
specificity and efficacy. The precise mechanisms governing the cellular uptake of CPPs remain ambiguous; however,
electrostatic interactions between positively charged amino acids and negatively charged glycosaminoglycans on the
membrane, particularly heparan sulfate proteoglycans, are considered the initial crucial step for CPP uptake. Clinical
trials have highlighted the potential of CPPs in diagnosing and treating various diseases, including cancer, central
nervous system disorders, eye disorders, and diabetes. This review provides a comprehensive overview of CPP
classifications, potential applications, transduction mechanisms, and the most relevant algorithms to improve the
accuracy and reliability of predictions in CPP development.</p>
<p><img alt="Illustrative figure" loading="lazy" decoding="async" fetchpriority="auto" width="4126" height="2939" src="/_astro/illustration.D4qgdVqi_1dCMXW.webp" ></p>
<p class="publication-caption">Intracellular entry pathways for CPPs. CPPs utilize two primary mechanisms for cellular
entry: energy-dependent endocytosis and energy-independent direct translocation across the lipid bilayer.</p> </div> </details> </div> </article><article id="paper-2024-02" class="publication-card" style="--publication-body-img-width: 68%"> <div class="publication-media"> <img src="/_astro/thumbnail.DGe7Raye.png" alt="First page thumbnail of publication" loading="lazy"> </div> <div class="publication-body"> <h3> <a href="#paper-2024-02">Cancer-targeting applications of cell-penetrating peptides</a> </h3> <p class="publication-authors">Liliana M. Moreno-Vargas<sup>*</sup> and Diego Prada-Gracia<sup>*</sup></p> <p class="publication-links"> <a href="https://doi.org/10.3390/ijms26010002" target="_blank" rel="noreferrer">
Print
</a>    </p> <details class="publication-details"> <summary> <span class="summary-closed">Show abstract</span> <span class="summary-open">Hide abstract</span> </summary> <div class="publication-body-expanded"> <p>Cell-penetrating peptides (CPPs) offer a unique and efficient mechanism for delivering therapeutic agents directly into
cancer cells. These peptides can traverse cellular membranes, overcoming one of the critical barriers in drug delivery
systems. In this review, we explore recent advancements in the application of CPPs for cancer treatment, focusing on
mechanisms, delivery strategies, and clinical potential. The review highlights the use of CPP-drug conjugates, CPP-based
vaccines, and their role in targeting and inhibiting tumor growth.</p>
<p><img alt="Illustrative figure" loading="lazy" decoding="async" fetchpriority="auto" width="4560" height="3200" src="/_astro/illustration.eVVXRTQ8_2uF3DG.webp" ></p>
<p class="publication-caption">CPPs with Intrinsic Anticancer Activity. This figure presents CPPs that exert therapeutic
effects through intrinsic biological functions, independent of cargo.</p> </div> </details> </div> </article> </div> </section><section class="publications-year" aria-label="Publications 2023" id="year-2023"> <h2> <a href="#year-2023">2023</a> </h2> <div class="publications-grid"> <article id="paper-2023-01" class="publication-card" style="--publication-body-img-width: 68%"> <div class="publication-media"> <img src="/_astro/thumbnail.D-nA32zy.png" alt="First page thumbnail of publication" loading="lazy"> </div> <div class="publication-body"> <h3> <a href="#paper-2023-01">Opitz GBBB syndrome with total anomalous pulmonary venous connection: a new MID1 gene variant</a> </h3> <p class="publication-authors">Maryangel Perea‐Cabrera, Javier T Granados‐Riveron, Begoña Segura‐Stanford, Liliana M Moreno‐Vargas, Diego Prada‐Gracia, Mari C Moran‐Espinosa, Julio Erdmenger, Hector Diaz‐Garcia, Rocío Sánchez‐Urbina<sup>*</sup></p> <p class="publication-links"> <a href="https://doi.org/10.1002/mgg3.2234" target="_blank" rel="noreferrer">
Print
</a>    </p> <details class="publication-details"> <summary> <span class="summary-closed">Show abstract</span> <span class="summary-open">Hide abstract</span> </summary> <div class="publication-body-expanded"> <p>Opitz GBBB syndrome (GBBB) is an X-linked disease characterized by midline defects, including congenital heart defects.
We present our diagnostic approach to the identification of GBBB in a consanguineous family in which two males siblings
were concordant for a total anomalous connection of pulmonary veins and minor facial dysmorphias.</p>
<p><img alt="Illustrative figure" loading="lazy" decoding="async" fetchpriority="auto" width="2128" height="1493" src="/_astro/illustration.BM1eJfRQ_1sD6yr.webp" ></p>
<p class="publication-caption">The three-dimensional structure of E3 ubiquitin-protein ligase Midline-1, as determined
by molecular modeling and the spatial locations of surface mutations.</p> </div> </details> </div> </article> </div> </section><section class="publications-year" aria-label="Publications 2022" id="year-2022"> <h2> <a href="#year-2022">2022</a> </h2> <div class="publications-grid"> <article id="paper-2022-01" class="publication-card" style="--publication-body-img-width: 68%"> <div class="publication-media"> <img src="/_astro/thumbnail.SLSHnUOp.png" alt="First page thumbnail of publication" loading="lazy"> </div> <div class="publication-body"> <h3> <a href="#paper-2022-01">Exploring the druggability of the binding site of aurovertin, an exogenous allosteric inhibitor of FOF1-ATP synthase</a> </h3> <p class="publication-authors">Luis Fernando Cofas-Vargas, Paola Mendoza-Espinosa, Luis Pablo Avila-Barrientos, Diego Prada-Gracia, Héctor Riveros-Rosas, Enrique García-Hernández</p> <p class="publication-links"> <a href="https://doi.org/10.1002/mgg3.2234" target="_blank" rel="noreferrer">
Print
</a>    </p> <details class="publication-details"> <summary> <span class="summary-closed">Show abstract</span> <span class="summary-open">Hide abstract</span> </summary> <div class="publication-body-expanded"> <p>In addition to playing a central role in the mitochondria as the main producer of ATP, FOF1-ATP synthase performs
diverse key regulatory functions in the cell membrane. Its malfunction has been linked to a growing number of human
diseases, including hypertension, atherosclerosis, cancer, and some neurodegenerative, autoimmune, and aging diseases.
Furthermore, inhibition of this enzyme jeopardizes the survival of several bacterial pathogens of public health concern.
Therefore, FOF1-ATP synthase has emerged as a novel drug target both to treat human diseases and to combat antibiotic
resistance. In this work, we carried out a computational characterization of the binding sites of the fungal antibiotic
aurovertin in the bovine F1 subcomplex, which shares a large identity with the human enzyme. Molecular dynamics
simulations showed that although the binding sites can be described as preformed, the inhibitor hinders inter-subunit
communications and exerts long-range effects on the dynamics of the catalytic site residues. End-point binding free
energy calculations revealed hot spot residues for aurovertin recognition. These residues were also relevant to
stabilize solvent sites determined from mixed-solvent molecular dynamics, which mimic the interaction between aurovertin
and the enzyme, and could be used as pharmacophore constraints in virtual screening campaigns. To explore the
possibility of finding species-specific inhibitors targeting the aurovertin binding site, we performed free energy
calculations for two bacterial enzymes with experimentally solved 3D structures. Finally, an analysis of bacterial
sequences was carried out to determine conservation of the aurovertin binding site. Taken together, our results
constitute a first step in paving the way for structure-based development of new allosteric drugs targeting FOF1-ATP
synthase sites of exogenous inhibitors.</p>
<p><img alt="Illustrative figure" loading="lazy" decoding="async" fetchpriority="auto" width="1480" height="1162" src="/_astro/illustration.D2lyRZYT_Z1On4r8.webp" ></p>
<p class="publication-caption">Schematic representation of the ATP synthase architecture and the binding sites of
exogenous and endogenous allosteric inhibitors.</p> </div> </details> </div> </article> </div> </section> </section>  </section> </main> <footer> <p>
Computational Biology and Drug Design Research Unit · Federico Gómez Children's
              Hospital of Mexico · Mexican National Institute of Health
</p> </footer> </div> <script type="module">const u=document.documentElement,l=document.querySelector(".site-header"),c=document.querySelector(".internal-page-shell"),a=()=>{if(!l)return;const e=l.getBoundingClientRect(),o=Array.from(l.querySelectorAll("*"));let t=e.bottom;for(const i of o){const n=i.getBoundingClientRect();n.bottom>t&&(t=n.bottom)}const s=Math.ceil(t-e.top)+1;u.style.setProperty("--internal-occlusion-height",`${s}px`)},r=(e=!1)=>{const o=window.location.hash;if(!o||o.length<2||!c)return;const t=document.getElementById(decodeURIComponent(o.slice(1)));if(!t)return;const s=c.getBoundingClientRect(),n=t.getBoundingClientRect().top-s.top+c.scrollTop-10;c.scrollTo({top:Math.max(0,n),behavior:e?"smooth":"auto"})};window.addEventListener("hashchange",()=>r(!0));window.addEventListener("resize",a);document.addEventListener("click",e=>{const o=e.target instanceof Element?e.target.closest('a[href^="#"]'):null;if(!o)return;const t=o.getAttribute("href")??"";if(!(t.length<2)){if(e.preventDefault(),window.location.hash===t){r(!0);return}history.pushState(null,"",t),r(!0)}});requestAnimationFrame(()=>{a(),r(!1)});</script> </body> </html>